3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
55
Breast Neoplasms
29
Neoplasms
25
Lung Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Colorectal Neoplasms
6
Colonic Neoplasms
6
Polycystic Ovary Syndrome
5
Pancreatic Neoplasms
5
Obesity
5
Lymphoma
5
Fatigue
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Lymphedema
4
Esophageal Neoplasms
4
Brain Neoplasms
4
Stomach Neoplasms
3
Prostatic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Leukemia
3
Hematologic Neoplasms
3
Skin Neoplasms
2
Sarcopenia
2
Recurrence
2
Rectal Neoplasms
2
Peripheral Nervous System Diseases
2
Neoplasm Metastasis
2
Melanoma
2
Interventions
Gemcitabine
56
pembrolizumab
50
Cisplatin
43
Magnetic Resonance Spectroscopy
27
enfortumab vedotin
22
Specimen Handling
22
Nivolumab
22
Cystectomy
18
durvalumab
16
Carboplatin
16
avelumab
15
Mitomycin
14
atezolizumab
13
Docetaxel
13
Cystoscopy
12
Fluorouracil
11
Radiation
9
Transurethral Resection of Bladder
8
Radiotherapy
8
Ipilimumab
8
sacituzumab govitecan
7
Standard of Care
7
Radiosurgery
7
Paclitaxel
7
Immunoglobulin G
7
Disulfides
7
erdafitinib
6
cemiplimab
6
Surveys and Questionnaires
6
Surgical Procedures, Operative
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Exercise
×
1 year
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled